
First human trial begins for Bundibugyo Ebola vaccine
An experimental vaccine targeting the Bundibugro strain of Ebola has entered its first-in-human phase to evaluate safety and immune response. It is one of four Bundibugro vaccines in development; existing Zaire-targeted vaccines do not work against Bundibugro. Oxford-led trials will be followed by a second small Uganda study and a larger efficacy trial in DR Congo. The Serum Institute has produced 600,000 doses if trials succeed. The DR Congo outbreak has over 2,500 confirmed cases and about 1,000 deaths.
